Stockscreener 앱 받기
1.23
0.81%
-0.01
전일 마감가:
$1.24
열려 있는:
$1.22
하루 거래량:
1.59M
Relative Volume:
0.55
시가총액:
$276.42M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.5802
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
+0.00%
1개월 성능:
-2.38%
6개월 성능:
+10.81%
1년 성능:
-41.71%
1일 변동 폭
$1.20
$1.25
1주일 범위
$1.20
$1.35
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.23 | 278.67M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics Inc Stock Analysis and ForecastTop Performing Stocks & Low Risk Investment Trading - earlytimes.in
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care - Traders Union
ALLO (Allogene Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2025) - GuruFocus
Will breakout in Allogene Therapeutics Inc. lead to full recovery2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy - Investing.com Canada
VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO] - TradingView
Applying Elliott Wave Theory to Allogene Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedQuarterly Trade Report & Low Risk Entry Point Guides - newser.com
Allogene Therapeutics CEO advocates cell therapy innovation at Jefferies conference - Traders Union
Published on: 2025-11-14 03:15:46 - newser.com
How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.2025 Market Outlook & Momentum Based Trading Ideas - newser.com
Published on: 2025-11-12 16:30:24 - newser.com
November 2025's Promising Penny Stocks To Watch - simplywall.st
Published on: 2025-11-12 02:14:40 - newser.com
Allogene Therapeutics (ALLO) Receives a Buy from H.C. Wainwright - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Allogene Therapeutics Advances in CAR T Therapy Development - MSN
Allogene Therapeutics readies for key healthcare investor conferences - Traders Union
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene (NASDAQ: ALLO) to join 3 conferences: TD Cowen, Jefferies London, Piper Sandler - Stock Titan
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):